ArticlePloS one2025
Neuronal differentiation of human dental pulp stem cells induced by co-treatment of ergothioneine.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing neurogenic differentiation of dental stem cells: a critical review of induction strategies and functional validation.Frontiers in dental medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHuman dental pulp stem cells (hDPSCs) are promising adult stem cells that present multilineage differentiation ability. Interestingly, ergothioneine (ERGO) has the potential to uptake into the organic cation transporter N1 (OCTN1) to promote neuronal differentiation. Therefore, this study aims to demonstrate the effect of co-treatment of ergothioneine on the neuronal differentiation of hDPSCs.
methodsThe hDPSCs were established from the impacted third molars. Subsequently, the hDPSCs investigated the cell viability with ergothioneine at concentrations of 0-500 µM for 30 hours. The non-cytotoxic concentration of ergothioneine was synergistically induced with the neuronal induction medium. The characteristics of differentiated cells were verified as neuronal cells (d-hDPSCs) by identification of the Nissl substance. The optimal concentration of ergothioneine, which triggered the highest neuronal differentiation of hDPSCs, was further confirmed by neuronal phenotypes via immunofluorescent staining, gene expression, and the ability of neurotransmitter release by intracellular calcium oscillation.
resultsThe isolated cells from human dental pulp tissue were characterized as mesenchymal stem cells (MSCs), verified as hDPSCs. The cellular toxicity of ergothioneine was not observed up to 500 µM for 30 hours. The d-hDPSCs presented a neuronal-like shape and positively expressed the Nissl substance. Interestingly, the highest number of neuronal-like cells was detected at 500 µM of ergothioneine. These neuronal-like cells exhibited the synaptic vesicle glycoprotein 2A (SV2A) expression and dynamic change of intracellular Ca2+, suggesting potential functional neuronal characteristics. Furthermore, co-treatment of ergothioneine at 500 µM triggered neurogenic maturation by decreasing Nestin and NES expression and increasing Beta-III tubulin, TUBB3, and microtubule-associated protein 2 (MAP2) expression, respectively.
conclusionCo-treatment of ergothioneine at 500 µM can enhance neuronal differentiation, which has the potential to promote neurogenic maturation. Therefore, these findings suggest the alternative of using hDPSCs and the potential of ergothioneine co-treatment as stem cell-based therapy for further transplantation to cure various neurological diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.